DexCom, Inc. vs Vanguard Information Technology Index Fund ETF — how do they compare? DexCom, Inc. trades at $83.7 (market cap $31.86B), while Vanguard Information Technology Index Fund ETF trades at $127.7 (market cap $170.20B). The key difference: Vanguard Information Technology Index Fund ETF is far larger — about 5.3× DexCom, Inc.'s market cap, and Vanguard Information Technology Index Fund ETF is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Vanguard Information Technology Index Fund ETF for 129 Days on average.
| DXCM | VGT | |
|---|---|---|
Market Cap | $31.86B | $170.20B |
Volume | 3,607,070 | 5,132,883 |
Sector | Health | — |
52-Week High | $92.34 | $129.79 |
52-Week Low | $54.84 | $83.59 |
Typical Hold Time | 62 Days | 129 Days |
Enterprise Value | $31.32B | — |
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
VGT trades at $127.00, down 1.83% today but maintains a bullish technical outlook with strong moving average support. The ETF's focus on pure-play technology stocks like Nvidia, Apple, and Microsoft has delivered exceptional historical returns, averaging over 17% annually for two decades according to The Motley Fool (2026-10-03). Recent institutional buying activity signals continued confidence in the tech sector's growth prospects.
While VGT offers concentrated tech exposure with low fees, investors face sector concentration risk and potential AI slowdown concerns. The ETF's exclusion of major tech names like Google and Amazon due to classification rules creates unexpected portfolio gaps. Current technical strength supports near-term upside, but macroeconomic headwinds could pressure tech valuations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →